Marco Valgimigli1,2, Francesco Costa2,3, Yuliya Lokhnygina4, Robert M Clare4, Lars Wallentin5, David J Moliterno6, Paul W Armstrong7, Harvey D White8, Claes Held5, Philip E Aylward9, Frans Van de Werf10, Robert A Harrington11, Kenneth W Mahaffey11, Pierluigi Tricoci4. 1. Swiss Cardiovascular Center Bern, Bern University Hospital, CH-3010 Bern, Switzerland. 2. Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. 3. Department of Clinical and Experimental Medicine, Policlinic 'G. Martino', University of Messina, Messina, Italy. 4. Duke Clinical Research Institute, Durham, NC, USA. 5. Department of Medical Sciences, Cardiology, and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 6. Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA. 7. Division of Cardiology, University of Alberta, Edmonton, AB, Canada. 8. Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand. 9. South Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, SA, Australia. 10. Department of Cardiology, University of Leuven, Leuven, Belgium. 11. Department of Medicine, Stanford University, Stanford, CA, USA.
Abstract
AIMS: Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases bleeding to a similar extent. We sought to determine the prognostic impact of myocardial infarction (MI) vs. bleeding during an extended follow-up period to gain insight into the trade-off between efficacy and safety among patients after ACS. METHODS AND RESULTS: In 12 944 patients with non-ST-segment elevation ACS from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated the relative impact of MI and bleeding occurring >30 days post-ACS and subsequent all-cause mortality. Bleeding was graded according to Bleeding Academic Research Consortium (BARC) criteria. MI was associated with a five-fold increase in mortality. BARC type 2 and 3, but not type 1, bleeding had a significant impact on mortality. MI was associated with a greater risk of mortality compared with BARC 2 [relative risk (RR) 3.5; 95% confidence interval (CI) 2.08-4.77; P < 0.001] and BARC 3a bleeding (RR 2.23; 95% CI 1.36-3.64; P = 0.001), and a risk similar to BARC 3b bleeding (RR 1.37; 95% CI 0.81-2.30; P = 0.242). Risk of death after MI was significantly lower than after BARC 3c bleeding (RR 0.22; 95% CI 0.13-0.36; P < 0.001). MI and bleeding had similar time-associations with mortality, which remained significant for several months, still being higher early after the event. CONCLUSION: In patients treated with antiplatelet therapy after ACS, both MI and bleeding significantly impacted mortality with similar time-dependency. Although BARC 2 and 3a bleeding were less prognostic for death than MI, the risk of mortality was equivalent between BARC 3b bleeding and MI, and was higher following BARC 3c bleeding. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Dual antiplatelet therapy reduces non-fatal ischaemic events after acute coronary syndrome (ACS) but increases bleeding to a similar extent. We sought to determine the prognostic impact of myocardial infarction (MI) vs. bleeding during an extended follow-up period to gain insight into the trade-off between efficacy and safety among patients after ACS. METHODS AND RESULTS: In 12 944 patients with non-ST-segment elevation ACS from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, we investigated the relative impact of MI and bleeding occurring >30 days post-ACS and subsequent all-cause mortality. Bleeding was graded according to Bleeding Academic Research Consortium (BARC) criteria. MI was associated with a five-fold increase in mortality. BARC type 2 and 3, but not type 1, bleeding had a significant impact on mortality. MI was associated with a greater risk of mortality compared with BARC 2 [relative risk (RR) 3.5; 95% confidence interval (CI) 2.08-4.77; P < 0.001] and BARC 3a bleeding (RR 2.23; 95% CI 1.36-3.64; P = 0.001), and a risk similar to BARC 3b bleeding (RR 1.37; 95% CI 0.81-2.30; P = 0.242). Risk of death after MI was significantly lower than after BARC 3c bleeding (RR 0.22; 95% CI 0.13-0.36; P < 0.001). MI and bleeding had similar time-associations with mortality, which remained significant for several months, still being higher early after the event. CONCLUSION: In patients treated with antiplatelet therapy after ACS, both MI and bleeding significantly impacted mortality with similar time-dependency. Although BARC 2 and 3a bleeding were less prognostic for death than MI, the risk of mortality was equivalent between BARC 3b bleeding and MI, and was higher following BARC 3c bleeding. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Dhruv S Kazi; Thomas K Leong; Tara I Chang; Matthew D Solomon; Mark A Hlatky; Alan S Go Journal: J Am Coll Cardiol Date: 2015-04-14 Impact factor: 24.094
Authors: Marco Valgimigli; Francesco Costa; Robert Byrne; Michael Haude; Andreas Baumbach; Stephan Windecker Journal: EuroIntervention Date: 2015-05 Impact factor: 6.534
Authors: Marc P Bonaca; Deepak L Bhatt; Marc Cohen; Philippe Gabriel Steg; Robert F Storey; Eva C Jensen; Giulia Magnani; Sameer Bansilal; M Polly Fish; Kyungah Im; Olof Bengtsson; Ton Oude Ophuis; Andrzej Budaj; Pierre Theroux; Mikhail Ruda; Christian Hamm; Shinya Goto; Jindrich Spinar; José Carlos Nicolau; Robert G Kiss; Sabina A Murphy; Stephen D Wiviott; Peter Held; Eugene Braunwald; Marc S Sabatine Journal: N Engl J Med Date: 2015-03-14 Impact factor: 91.245
Authors: Steven V Manoukian; Frederick Feit; Roxana Mehran; Michele D Voeltz; Ramin Ebrahimi; Martial Hamon; George D Dangas; A Michael Lincoff; Harvey D White; Jeffrey W Moses; Spencer B King; E Magnus Ohman; Gregg W Stone Journal: J Am Coll Cardiol Date: 2007-03-09 Impact factor: 24.094
Authors: Francesco Costa; Jan G Tijssen; Sara Ariotti; Sara Giatti; Elisabetta Moscarella; Paolo Guastaroba; Rossana De Palma; Giuseppe Andò; Giuseppe Oreto; Felix Zijlstra; Marco Valgimigli Journal: J Am Heart Assoc Date: 2015-12-07 Impact factor: 5.501
Authors: Felice Gragnano; Elisabetta Moscarella; Paolo Calabrò; Arturo Cesaro; Pia Clara Pafundi; Alfonso Ielasi; Giuseppe Patti; Ilaria Cavallari; Emilia Antonucci; Plinio Cirillo; Pasquale Pignatelli; Gualtiero Palareti; Francesco Pelliccia; Carlo Gaudio; Ferdinando Carlo Sasso; Vittorio Pengo; Paolo Gresele; Rossella Marcucci Journal: Intern Emerg Med Date: 2020-06-15 Impact factor: 3.397
Authors: Alexander C Fanaroff; Derek Cyr; Megan L Neely; Jeffery Bakal; Harvey D White; Keith A A Fox; Paul W Armstrong; Renato D Lopes; E Magnus Ohman; Matthew T Roe Journal: Circ Cardiovasc Qual Outcomes Date: 2018-12
Authors: Benjamin A T Rodriguez; Arunoday Bhan; Andrew Beswick; Peter C Elwood; Teemu J Niiranen; Veikko Salomaa; David-Alexandre Trégouët; Pierre-Emmanuel Morange; Mete Civelek; Yoav Ben-Shlomo; Thorsten Schlaeger; Ming-Huei Chen; Andrew D Johnson Journal: Am J Hum Genet Date: 2020-07-09 Impact factor: 11.025